The Cooper Companies, Inc. (NYSE:COO) Receives $401.30 Average PT from Analysts

Shares of The Cooper Companies, Inc. (NYSE:COO) have earned a consensus rating of “Moderate Buy” from the eight research firms that are covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $401.30.

A number of research analysts have recently commented on the company. Mizuho restated a “buy” rating and issued a $440.00 target price on shares of Cooper Companies in a research note on Monday, August 28th. Citigroup reduced their price objective on Cooper Companies from $440.00 to $420.00 in a research report on Monday, October 2nd. Morgan Stanley began coverage on Cooper Companies in a research report on Thursday, September 28th. They set an “equal weight” rating and a $410.00 price objective for the company. StockNews.com began coverage on Cooper Companies in a research report on Thursday, October 5th. They set a “hold” rating for the company. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $420.00 price objective on shares of Cooper Companies in a research report on Thursday, August 31st.

Cooper Companies Trading Up 0.4 %

NYSE COO opened at $330.57 on Friday. The stock has a market cap of $16.37 billion, a P/E ratio of 59.78, a price-to-earnings-growth ratio of 2.60 and a beta of 0.94. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.99 and a current ratio of 1.72. The stock has a 50 day simple moving average of $327.00 and a two-hundred day simple moving average of $359.96. Cooper Companies has a fifty-two week low of $301.45 and a fifty-two week high of $399.62.

Cooper Companies (NYSE:COO) last released its earnings results on Wednesday, August 30th. The medical device company reported $3.35 EPS for the quarter, beating analysts’ consensus estimates of $3.34 by $0.01. The company had revenue of $930.20 million during the quarter, compared to analysts’ expectations of $899.77 million. Cooper Companies had a return on equity of 8.17% and a net margin of 7.83%. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $3.19 EPS. On average, analysts forecast that Cooper Companies will post 12.81 earnings per share for the current year.

Institutional Trading of Cooper Companies

Several large investors have recently modified their holdings of the company. Colonial Trust Co SC purchased a new position in Cooper Companies during the first quarter valued at $41,000. First Trust Direct Indexing L.P. lifted its position in Cooper Companies by 4.6% during the second quarter. First Trust Direct Indexing L.P. now owns 1,226 shares of the medical device company’s stock valued at $470,000 after purchasing an additional 54 shares in the last quarter. B. Riley Wealth Advisors Inc. lifted its position in Cooper Companies by 163.4% during the second quarter. B. Riley Wealth Advisors Inc. now owns 1,886 shares of the medical device company’s stock valued at $723,000 after purchasing an additional 1,170 shares in the last quarter. Vanguard Personalized Indexing Management LLC lifted its position in Cooper Companies by 14.9% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 3,303 shares of the medical device company’s stock valued at $1,266,000 after purchasing an additional 428 shares in the last quarter. Finally, Truist Financial Corp lifted its position in Cooper Companies by 2.9% during the second quarter. Truist Financial Corp now owns 25,712 shares of the medical device company’s stock valued at $9,859,000 after purchasing an additional 728 shares in the last quarter. Institutional investors own 96.31% of the company’s stock.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific.